DATE : 2023-05-14
ATTENDEES : PERSON125, PERSON126


SUMMARY
- The Commission's statement was supposed to be read out yesterday during the debate, but it was not.
- Access to affordable pharmaceutical products in poor developing countries and LDCs is essential to attain the proposed EU development goals.
- The WTO decision and the protocol to the TRIPS Agreement represent just a part of the solution to the problem of access to medicines and public health.
- Other measures to improve health care and infrastructure are equally indispensable.
- The Council, the European Parliament and the Commission worked hard to adopt Regulation (EC) No 816/2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems.
- They support the use of the 'flexibilities' built into the TRIPS Agreement and the Doha Declaration.
- EU does not intend to negotiate pharmaceutical-related provisions affecting public health and access to medicines.


Minuted by: Team Synapse